Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ascendis Phase III Data Gives TransCon PTH An Edge In Hypoparathyroidism

Executive Summary

The firm plans to submit to the US FDA in the third quarter and with the European Medicines Agency in the fourth quarter based on positive Phase III study results.

You may also be interested in...



Keeping Track: Pluvicto Boosts Novartis In Radiotherapy; BMS Builds Out IO Estate With Opdualag

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Finance Watch: Public Markets Open Back Up For Biopharma Offerings

Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains. 

Ascendis Will Take On Daily Genotropin With Weekly Skytrofa

Ascendis’s growth hormone deficiency drug Skytrofa will offer a convenience advantage as a weekly injectable. But the label does not clearly delineate superiority shown in a Phase III trial.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel